Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Enterprise Value (2019 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Enterprise Value data on record, last reported at -$333.3 million in Q1 2026.

  • On a quarterly basis, Enterprise Value fell 690.26% to -$333.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$333.3 million, a 690.26% decrease, with the full-year FY2025 number at -$197.5 million, up 18.04% from a year prior.
  • Enterprise Value reached -$333.3 million in Q1 2026 per FULC's latest filing, down from -$197.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for FULC hit a ceiling of -$30.1 million in Q3 2023 and a floor of -$333.3 million in Q1 2026.
  • A 5-year average of -$106.4 million and a median of -$47.1 million in 2025 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 66.93% in 2022, then plummeted 690.26% in 2026.
  • Tracing FULC's Enterprise Value over 5 years: stood at -$35.1 million in 2022, then tumbled by 573.03% to -$236.2 million in 2023, then decreased by 2.03% to -$241.0 million in 2024, then rose by 18.04% to -$197.5 million in 2025, then plummeted by 68.74% to -$333.3 million in 2026.
  • Business Quant data shows Enterprise Value for FULC at -$333.3 million in Q1 2026, -$197.5 million in Q4 2025, and -$47.1 million in Q3 2025.